Myelin and lymphocyte protein 2 (MAL2)

Myelin and lymphocyte protein 2 (MAL2) is a 19-kDa tetra-transmembrane protein in the MAL protein family, primarily involved in polarized trafficking and apical transcytosis of membrane proteins in epithelial and other polarized cells[1][2][5]. Localized to cholesterol-rich lipid raft domains, MAL2 regulates vesicular transport pathways between endosomes, Golgi, and the apical plasma membrane, including the transport of key immunological and structural proteins[2][5]. MAL2 is expressed in various epithelial tissues, neurons, dendritic cells, and mast cells[2][5]. In cancer, MAL2 is often overexpressed and associated with poor prognosis, playing key roles in cell proliferation, invasion, metastasis, immune evasion, and regulation of signaling pathways such as PI3K/AKT/mTOR and MAPK[1][2][3]. Unique interactions with proteins like tumor protein D52 and MUC1, as well as EGFR, have implicated MAL2 in multiple tumor progression mechanisms[1][2][3]. There are currently no approved drugs directly targeting MAL2, but preclinical evidence suggests it is a promising therapeutic and prognostic target for several malignancies[1][2][3]. The protein's role as either a tumor suppressor or progression factor may depend on context and tissue type[4][2].

Other names

T-cell differentiation protein 2malMAL proteolipid protein 2MAL2 proteolipid proteinprotein MAL2myelin and lymphocyte protein 2

No direct drugs, but inhibition/targeting of MAL2 experimentally suppresses tumor proliferation, migration, invasion, and affects pathways such as PI3K/AKT/SREBP-1 and MAPK/mTOR (as shown in breast, lung, and cholangiocarcinoma models)[1][2][3]